Moby6d agoneutral
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call SummaryMoby summary of Recursion Pharmaceuticals, Inc.'s Q2 2026 earnings call
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
357last 24h
2376last 7d
428● bullish (7d)
221● bearish (7d)
202publishers
MarketBeat6d agoneutral
Recursion Pharmaceuticals Q2 Earnings Call HighlightsRecursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028. The
Motley Fool96d agoneutral
Recursion (RXRX) Q1 2026 Earnings TranscriptNajat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.
MarketBeat97d agoneutral
Recursion Pharmaceuticals Q1 Earnings Call HighlightsRecursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President